Prof. em. Dr. med. Thomas Cerny was elected as a new member to the Board of Directors at today’s Annual General Meeting of Shareholders. Thomas Cerny co-founded ProteoMediX in 2010 and was involed from the beginning in the research and clinical development of ProteoMediX' first product. He was the Director of Oncology/Haematology at the Kantonsspital St. Gallen and Professor for Medical Oncology at the University of Berne until his recent retirment in 2017. Thomas Cerny is still an active expert and member of several oncology-focused organizations such as the Swiss Cancer League and the HMEC of Swissmedic.